Dose escalation trial of BNT152+153 in patients with cancer
This is a very early study, called a Phase 1 trial, looking into a new potential cancer treatment named BNT152+153. The main goal is to find a safe and tolerable dose of this new drug when given to people for the very first time. Researchers also want to understand what happens to the drug in the body. This study is for adult patients with various types of solid cancers that have either spread to other parts of the body (metastatic) or cannot be removed through surgery (unresectable). Because it's an early-stage study, it's focused on safety and understanding the drug, rather than proving it cures cancer. Patients taking part will be carefully monitored.
At a glance
What is this study about?
This study is a very early look at a new medication called BNT152+153 for people with certain types of advanced cancer. When a new medicine is developed, it goes through several stages of testing to make sure it's safe and effective. This particular study is called a 'Phase 1' trial, which means it's one of the very first times this treatment is being given to humans.
The main aim of this Phase 1 study is to find the right dose of BNT152+153 that can be given safely without causing too many side effects. Researchers will start with a very small dose and carefully increase it for different groups of patients, watching closely for any reactions. They also want to understand how the drug behaves in the body – for example, how it's absorbed, where it goes, and how it's removed.
This study is important because it's the first step in seeing if this new treatment has the potential to help people with cancer. If it seems safe and there are no major concerns, it could move on to later stages of testing involving more patients, where researchers would then look more closely at whether it can shrink tumours or improve health.
Key takeaways
- This is an early-stage (Phase 1) study for a new cancer treatment (BNT152+153).
- Its main goal is to find a safe dose and understand how the drug works in the body.
- It's for adults with various solid cancers that have spread or can't be operated on.
- Participation involves frequent clinic visits and close monitoring.
- There might be potential benefits from a new treatment, but also unknown risks and side effects.
- You can leave the study at any point without affecting your regular care.
Who may be eligible?
To be considered for this study, you must be an adult, 18 years old or older. The study is open to both men and women. Importantly, you need to have a type of solid cancer that has either spread to other parts of your body (this is called metastatic cancer) or cannot be removed by an operation (this is called unresectable cancer).
There might be other specific health requirements or conditions that would mean you can or cannot join, but these details are not available here. Things like your general health, other medical conditions you have, and any other treatments you've had in the past could be important factors.
If you're interested, it's really important to talk to your doctor. They can check if you meet all the detailed criteria for this specific study and discuss if it might be a suitable option for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have a diagnosis of solid cancer?
- Has your cancer spread to other parts of your body, or can it not be removed by surgery?
- Are you open to trying a new treatment that is in its very early stages of testing?
- Are you able to attend regular clinic visits for monitoring?
What does participation involve?
If you decide to take part in this study, you would receive the new treatment, BNT152+153. Because this is an early-stage study, you would have frequent visits to the clinic, especially at the beginning, so that the research team can carefully monitor how you respond to the new drug. These visits would likely involve various medical checks, such as blood tests, physical examinations, and possibly scans to see how your cancer is doing.
The study would involve taking a new medication, which might be given in different ways, such as an injection or an infusion, depending on the drug. The research team would explain exactly how and when you would receive the treatment. The total duration of your participation would depend on how you respond to the treatment and the study plan, but early-stage studies often involve regular follow-up for a period of time, even after you stop receiving the treatment, to track your health and any long-term effects.
Potential risks and benefits
Locations (1)
- —UnverifiedCzechia
Common questions
What does 'Phase 1' mean?
Phase 1 means this is one of the very first times this new treatment is being given to people. The main focus is on finding a safe dose.
What kind of cancer is this study for?
This study is for adults with various types of solid cancers that have spread or cannot be removed by surgery.
Will this treatment cure my cancer?
This early-stage study is mainly looking at safety and finding a safe dose, not whether it can cure cancer. It's too soon to know if it will shrink tumours.
Who can join the study?
Adults aged 18 and over, both men and women, with advanced solid cancers, might be eligible.
Can I stop being part of the study if I want to?
Yes, absolutely. You can withdraw from the study at any time, for any reason, and it won't affect your future medical care.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.